伊立替康联合洛铂治疗复发性广泛期小细胞肺癌(SCLC)的临床研究  

Clinical observation of combined chemotherapy of lobaplatin and irinotecan in the treatment of extensive relapsed small- cell lung cancer

作　　者：伍志新[1] 陈立军[1] 宋文军[1] 黄彬彬[2] 

机构地区：[1]湘潭市第一人民医院肿瘤内科,湖南湘潭411101 [2]湘潭市第一人民医院放疗科,湖南湘潭411101

出　　处：《现代肿瘤医学》2014年第6期1344-1346,共3页Journal of Modern Oncology

摘　　要：目的:观察伊立替康联合洛铂方案治疗复发性小细胞肺癌(SCLC)的疗效和毒副反应。方法:选取36例SCLC患者,予伊立替康200mg/m2加入生理盐水250ml中,稀释后静滴1.5h,第1天;洛泊35mg/m2加入5%葡萄糖500ml中,稀释后静滴2h,第1天,每21d为1个周期,2个周期后评价疗效和毒副反应。结果:36例均可评价疗效,完全缓解(CR)1例,部分缓解(PR)13例,疾病稳定(SD)11例,疾病进展(PD)11例,客观缓解率(ORR)为38.9%,疾病控制率(DCR)为69.4%,中位无进展生存期(PFS)为4.6个月,中位生存期(OS)为7.8个月。毒副反应主要为血液学毒性和消化道毒性,3/4级白细胞减少、血红蛋白减少和血小板减少发生率分别为41.7%(15/36)、50.0%(18/36)、72.2%(26/36);腹泻发生率为69.4%(25/36),其中3、4级腹泻为13.9%(5/36)。全组无毒性相关死亡。结论:伊立替康联合洛铂方案用于治疗复发性SCLC有较好的疗效,毒副反应可耐受。Objective：To observe the efficacy and safety of chemotherapy consisted of lobaplatin and irinotecan for patients with relapsed（ extensive small -cell lung cancer,ED -SCLC ）. Methods：The first day,36 patients with SCLC were treated with 1. 5h intravenous infusion of CTP 200mg/m2 diluted in 250ml saline,lobaplatin 35mg/m2 di-luted in 500ml 5% glucose,with intravenous infusion for 2h,21 days as a cycle. Results：Thirty-six patients were evaluable for response,in which 1 achieved complete response and 13 partial responses,objective responses rate was 38. 9%,11 patients had stable disease and 11 progressive diseases. The disease control rate was 69. 4%. The median time for progression and overall survival was 4. 6 months and 7. 8 months,respectively. The main toxicity was the he-matologic toxicity and gastrointestinal tract side reaction,Grade 3,4 leucopenia was 41. 7%（15/36）,and neutropenia was 50. 0%（18/36）,and thrombocytopenia was 72. 2%（26/36）. Diarrhea was 69. 4%（25/36）,13. 9%（5/36） were grade 3,4. There was no treatment-related death. Conclusion：The combination of lobaplatin and irinotecan is highly active and tolerable in patients with chemotherapy mediate extensive relapsed small-cell lung cancer when it is administered as rescue treatment.

关 键 词：伊立替康 洛铂 小细胞肺癌 化疗 复发 

分 类 号：R734.2[医药卫生—肿瘤]